These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33915212)

  • 21. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peimine inhibits variants of SARS-CoV-2 cell entry via blocking the interaction between viral spike protein and ACE2.
    Wang WJ; Chen Y; Su WC; Liu YY; Shen WJ; Chang WC; Huang ST; Lin CW; Wang YC; Yang CS; Hou MH; Chou YC; Wu YC; Wang SC; Hung MC
    J Food Biochem; 2022 Oct; 46(10):e14354. PubMed ID: 35894128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
    Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
    Elife; 2021 Aug; 10():. PubMed ID: 34435953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uncovering the impact of SARS-CoV2 spike protein variants on human receptors: A molecular dynamics docking and simulation approach.
    Zaheer M; Ali N; Javed H; Munir R; Jamil N
    J Infect Public Health; 2023 Oct; 16(10):1544-1555. PubMed ID: 37566991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polysulfates Block SARS-CoV-2 Uptake through Electrostatic Interactions*.
    Nie C; Pouyan P; Lauster D; Trimpert J; Kerkhoff Y; Szekeres GP; Wallert M; Block S; Sahoo AK; Dernedde J; Pagel K; Kaufer BB; Netz RR; Ballauff M; Haag R
    Angew Chem Int Ed Engl; 2021 Jul; 60(29):15870-15878. PubMed ID: 33860605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins.
    Maffucci I; Contini A
    J Proteome Res; 2020 Nov; 19(11):4637-4648. PubMed ID: 32893632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A So-Far Overlooked Secondary Conformation State in the Binding Mode of SARS-CoV-2 Spike Protein to Human ACE2 and Its Conversion Rate Are Crucial for Estimating Infectivity Efficacy of the Underlying Virus Variant.
    Sevenich M; van den Heuvel J; Gering I; Mohrlüder J; Willbold D
    J Virol; 2022 Jul; 96(13):e0068522. PubMed ID: 35674432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2).
    Zeng MS; Yu WD; Wang HX; Liu JY; Xu PP
    Int J Biol Macromol; 2021 Jul; 183():2248-2261. PubMed ID: 34111482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
    Unni S; Aouti S; Thiyagarajan S; Padmanabhan B
    J Biosci; 2020; 45(1):. PubMed ID: 33184246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates.
    Schrörs B; Riesgo-Ferreiro P; Sorn P; Gudimella R; Bukur T; Rösler T; Löwer M; Sahin U
    PLoS One; 2021; 16(9):e0249254. PubMed ID: 34570776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioactive components of different nasal spray solutions may defeat SARS-Cov2: repurposing and in silico studies.
    Khan MF; Ansari WA; Ahamad T; Khan MA; Khan ZA; Sarfraz A; Khan MA
    J Mol Model; 2022 Jul; 28(8):212. PubMed ID: 35794497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Utility of Native MS for Understanding the Mechanism of Action of Repurposed Therapeutics in COVID-19: Heparin as a Disruptor of the SARS-CoV-2 Interaction with Its Host Cell Receptor.
    Yang Y; Du Y; Kaltashov IA
    Anal Chem; 2020 Aug; 92(16):10930-10934. PubMed ID: 32678978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Future of the COVID-19 Pandemic: How Good (or Bad) Can the SARS-CoV2 Spike Protein Get?
    Nugent MA
    Cells; 2022 Mar; 11(5):. PubMed ID: 35269476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations.
    Lazniewski M; Dermawan D; Hidayat S; Muchtaridi M; Dawson WK; Plewczynski D
    Methods; 2022 Jul; 203():498-510. PubMed ID: 35167916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?
    Belen-Apak FB; Sarialioglu F
    Med Hypotheses; 2020 Sep; 142():109743. PubMed ID: 32335456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2.
    Benton DJ; Wrobel AG; Roustan C; Borg A; Xu P; Martin SR; Rosenthal PB; Skehel JJ; Gamblin SJ
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33579792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.
    Boytz R; Słabicki M; Ramaswamy S; Patten JJ; Zou C; Meng C; Hurst BL; Wang J; Nowak RP; Yang PL; Sattler M; Stone RM; Griffin JD; Gray NS; Gummuluru S; Davey RA; Weisberg E
    J Med Virol; 2023 Jan; 95(1):e28157. PubMed ID: 36117402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents.
    Nandi S; Roy H; Gummadi A; Saxena AK
    Curr Drug Targets; 2021; 22(17):2006-2020. PubMed ID: 33687893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.